Candida: Difference between revisions

From IDWiki
Candida
No edit summary
m ()
 
(14 intermediate revisions by the same user not shown)
Line 1: Line 1:
==Background==
* Most common medically-important genus of yeast


*Most common medically-important genus of yeast
== Microbiology ==


===Microbiology===
* Budding yeast


*Budding yeast
== Organisms ==
*Human pathogens include:
**[[Candida albicans]]
**[[Candida dubliniensis]]
**[[Candida glabrata]]
**[[Candida tropicalis]]
**[[Candida parapsilosis]]
**[[Candida krusei]]
**[[Candida guilliermondii]]
**[[Candida auris]]
*Species that only rarely cause disease in humans include: [[Candida albidus]], [[Candida catenulate]], [[Candida chiropterorum]], [[Candida ciferrii]], [[Candida famata]], [[Candida haemulonii]], [[Candida humicola]], [[Candida inconspicua]], [[Candida kefyr]], [[Candida lambica]], [[Candida lipolytica]], [[Candida norvegensis]], [[Candida pelliculosa]], [[Candida pintolopesii]], [[Candida pulcherrima]], [[Candida rugosa]], [[Candida utilis]] and [[Candida zeylanoides]]


====Identification====
* ''[[C. albicans]]''
* ''[[C. dubliniensis]]''
* ''[[C. glabrata]]'': Fluconazole-resistant
* ''[[C. tropicalis]]''
* ''[[C. parapsilosis]]''
* ''[[C. krusei]]''
* ''[[C. auris]]''


*Any yeast that has growth on culture (blood, fluid, tissue) or seen on Gram stain gets subcultured to SAB-CG at 35º C.
== Clinical Presentation ==
*Do wet mount to confirm features of ''Candida.''
*'''Microscopy''' for chlamydospores, pseudohyphae, hyphae, arthroconidia, blastoconidia formation, budding, capsules, pigmentation.
**''C. glabrata'' is smaller, does not produce hyphae or pseudohyphae, produces blastoconidia, and grows as creamy yeast colonies.
**Non-glabrata spp. usually exhibit single buddings and can have pseudohyphae (rarely true septate hyphae). Cannot identify species based on microscopy alone.
*'''MALDI-ToF''' (Vitek MS) provides a species. If ''C. haemolunii'' or ''C. famata'' identified on Vitek, need to rule out ''C. auris''.
**If Vitek not ≥95% match, or identifies one of the two species above, then repeat the MALDI-ToF and set up Dalmau on cornmeal agar.
*'''Dalmau technique:''' growth in adverse conditions (bile oxgall and corn meal) to help identify differences between species of yeast.
**Light inoculum of single colony in a #-sign pattern with lines 1 inch apart. Cover streaks with coverslip and tamp down gently. Incubate at room temperature 18-72 hours.
**Examine after 18-24 hours. Look for thick-walled chlamydospores (terminal refractory circles), blastoconidia morphology, and presence of pseudohyphae. Then continue incubating, examining daily.
*Old-school enzymatic tests and assimilation assays.
*'''Temperature tolerance test''' at 35-37º C, 42º C, and 45º C
*'''[[Germ tube test]]:''' if positive, either ''C. albicans'' or ''C. dubliniensis''


{| class="wikitable"
* Most common: mouth, vagina, skin
!Species
* In immunocompromised, ICU, IVDU, or TPN patients: Esophagus, blood, CNS, endophthalmitis
!Colony
* Less common: joint
!Conidia
* IVDU: endocarditis
!Pseudohyphae
!Other
!Other Tests
|-
!''C. albicans''
|White to creamy, raised, pasty, smooth and soft, shiny and moist. May produce mycelial growth called “feet” or “roots”.
|Blastoconidia globose to oval.
|Well-developed, abundant with blastoconidia in clusters or grape-like arrangement at septa.
|Chlamydospores: round, large, thick-walled, usually single and mostly terminal forming on the tip of pseudohyphae, but some may be sessile. True hyphae may be present in older cultures.
|Growth at 42-45º C.
|-
!''C. dubliniensis''
|Cream-coloured, glistening, waxy, usually smooth.
|Blastoconidia subspherical, identical to C. albicans.
|Well-developed with blastoconidia in grape-like arrangement.
|Chlamydospores: round, large, thick-walled, usually in pairs, triplets, and clusters of 1-3 and mostly terminal. True hyphae may be present, especially in older culture.
|Usually no growth at 42-45º C.
|-
!''C. glabrata''
|Small, white to cream-coloured, shiny, pasty, and smooth.
|Terminal single budding, oval, and small. Typically arranged in dense groups.
|Absent, or rudimentary if present
|
|
|-
!''C. krusei''
|Cream-coloured to tannish-white. Flat, dry, ground-glass appearance. Spreading edge with a delicate feathery periphery.
|Elongate, ellipsoidal to cylindrical. Cells are liberated and arranged parallel to the main axis appearing like logs on the stream.
|Initially sparse, often present on prolonged incubation. Elondated and slender, with blastoconidia forming a cross-matchstick or treelike branching appearance at the septa.
|
|
|-
!''C. parapsilosis''
|White to creamy, shiny, moist, slightly flat, mostly smooth or partly or entirely wrinkled.
|Ovoid, single or in small clusters.
|Usually abundant, but may be slow to grow. Crooked or curved, relatively short, branched chains of pseudohyphae with clusters of blastoconidia at or between septa. Christmas-tree-like arrangement.
|Occasional presence of large hyphal elements called giant cells.
|
|-
!''C. tropicalis''
|Cream-coloured to semiwhite, dull, dry, soft, smooth and creamy. May be wrinkled or have a mycelial fringe near the edge. Can have feet (root mycelium) similar to C. albicans.
|Oval. Single or in small groups or short chains at or between septa of pseudohyphae.
|Very active growth. Abundant, long and branched. Blastoconidia produced in verticils from the pseudohyphae.
|True hyphae may be present.
|
|-
!''C. famata''
|White to cream coloured.
|Ellipsoidal.
|Absent.
|
|Weak growth at 40º C. Does not grow at 42º C.
|-
!''C. auris''
|White to cream-coloured. Pink to beige on chromogenic agar (depending on the agar).
|Oval or elongated yeast cells, singly or in pairs or groups.
|Absent.
|
|Grows well at 42º C. Variable growth at 45º C. Cycloheximide-susceptible. Usually fluconazole-resistant.
|-
!''C. guilliermondii''
|White to tan, slightly heaped, shiny, moist, and usually mucoid with smooth edge.
|Spherical to ellipsoidal.
|May be slow growing (up to 10 days), radiating from centre of masses of budding cells.
|Pseudohyphae not produced.
|May grow at 42 º C.
|}


===Epidemiology===
== Investigations ==


*Refer to [https://doi.org/10.1093/cid/cis697 Cleveland et al; CID 2012 55:1352].
* Urine culture if concern for cystitis
*The predominant species worldwide (and in Canada) is [[Candida albicans]], by a wide margin, followed by [[Candida glabrata]], [[Candida tropicalis]], and [[Candida parapsilosis]]
* Blood culture
*Non-''albicans'' species are becoming more common, globally, over the past three decades.
** '''Never ignore candidemia!'''
**[[Candida dubliniensis]] associated with HIV esophagitis
** Requires an '''ophthalmology''' consult to rule out endophthalmitis (1-3% of cases)
**[[Candida lusitaniae]] can develop resistance to amphotericin
** Echocardiogram if IVDU or prosthetic valve
**[[Candida guilliermondii]] is multidrug resistant
* Germ tube test (GTT)
**[[Candida auris]] still rare but may be emerging. It can be misidentified as other yeasts (most commonly ''C. haemulonii'', but also ''C. famata'', ''Saccharomyces cerevisiae'', and ''Rhodotorula glutinis'').
** If positive, indicates ''C. albicans'' or ''C. dubliniensis''
** Identifies fluconazole-sensitive Candidae


==Clinical Manifestations==
== Species and Resistance ==


===Fungemia===
{|

! Species
*See also [[candidemia]]
! Resistance pattern
*Risk factors include colonization, gastrointestinal mucosal disruption, total parenteral nutrition, and immunosuppression

===Oropharyngeal Candidiasis===

*Risk factors include immunosuppression including diabetes, inhaled corticosteroids, and denture used

===Esophageal Candidiasis===

*Risk factors include immunosuppression

===Vulvovaginal Candidiasis===

*Risk factors include colonization from recent antibiotic use, immunosuppression including diabetes, use of oral contraceptives, and pregnancy

===Candidal Infection of Skin and Nails===

*Risk factors include moisture and occlusion, immersion in water, and peripheral vascular disease
*Candidal skin infections can occur in moist body parts especially where skin occludes, and presents as a pruritic, erythematous rash with a poorly-defined edge that may have vesicles or pustules
*Candidal [[onychomycosis]] is most commonly caused by [[Candida albicans]] and [[Candida parapsilosis]], followed by [[Candida glabrata]] and [[Candida guilliermondii]]
*[[Paronychia]] can be caused by [[Candida albicans]]

===Cutaneous Congenital Candidiasis===

*Occurs in premature infants
*Presents as a generalized macular erythematous rash
*May become pustular, papular, or vescicular
*May desquamate

===Chronic Mucocutaneous Candidiasis===

*Occurs in people with T-cell defects, often related to [[Primary immunodeficiencies|primary immunodeficiency]]

===Urinary Tract Infection===

*Occurs in patients with diabetes, with indwelling urinary catheters, urinary obstruction, or recent urological procedures
*True infection most commonly occurs as a result of hematogenous dissemination rather than ascending infection or in patients who are immunocompromised
*''Candida'' species are a common contaminant of urine cultures, especially in women with vulvovaginal candidiasis
*They can also asymptomatically colonize the urinary system, causing asymptomatic candiduria

===Pulmonary Infections===

*Can occur from hematogenous spread
*Primary, isolated candidal [[pneumonia]] is very rare, and is associated with aspiration pneumonia
*[[Empyema]] can occur in patients with severe underlying diseases
*Candidal [[mediastinitis]] can happen after thoracic surgery, and is associated with high mortality
*[[Laryngitis]] or [[epiglottitis]] is rare and life-threatening

===Endocarditis===

*Most common fungal cause of [[infective endocarditis]]
*Risk factors include cardiac surgery, prior endocarditis, valvular disease, prosthetic valve, long-term central line, and intravenous drug use
*Clinically presents like bacterial [[Infective endocarditis|endocarditis]], but has a higher risk of embolic events
*Most commonly involves aortic and mitral valves

===Pericarditis and Myocarditis===

*Risk factors include thoracic surgery or immunosuppression
*[[Myocarditis]] is rare, occuring via hematogenous spread in immunocompromised patients
**Can have heart block and shock
*[[Pericarditis]] is also rare, often occurs after thoracic surgery, from hematogenous spread, or from contiguous spread

===CNS Infections===

*Occurs following neurosurgery or with [[ventricular shunt infection]] or with hematogenous spread
*Can cause [[brain abscess]], [[meningitis]], or [[stroke]]
*Meningitis can be difficult to diagnose, and requires a large volume of CSF for improved sensitivity

===Ocular Candidiasis===

*From direct inoculation after ocular surgery or trauma, or with hematogenous spread
*Includes [[keratitis]], [[chorioretinitis]], and [[endophthalmitis]]

===Bone and Joint Infections===

*Rare cause of [[osteomyelitis]] and [[septic arthritis]]
*Usually from hematogenous spread; other risk factors include surgery, trauma, intraarticular injection, or [[diabetic foot infection]]
*Symptoms may only become apparent months after initial hematogenous seeding, especially with vertebral osteomyelitis

===Intraabdominal Infection===

*Risk factors include abdominal perforation, abdominal surgery, solid organ transplantation, anastomotic leaks, pancreatitis, and peritoneal dialysis

==Investigations==

*Urine culture if concern for cystitis
*Blood culture
**'''Never ignore candidemia!'''
**Requires an '''ophthalmology''' consult to rule out endophthalmitis (1-3% of cases)
**Echocardiogram if IVDU or prosthetic valve
*Germ tube test (GTT)
**If positive, indicates ''Candida albicans'' or ''Candida dubliniensis''
**Identifies fluconazole-sensitive Candidae

==Management==

*Invasive infections should be treated with an echinocandin until species and susceptibilities are available

=== Management by Site of Infection ===
*Superficial infections involving skin or mucosa: can be treated with either topical preparations or low-dose oral fluconazole
*Candidemia: see [[Candidemia#Management|management of candidemia]]
*Bone and joint infections
**Osteomyelitis: likely needs surgical debridement and removal of any implants. Duration of antifungals not well studied, but likely 3 to 12 months
**Septic arthritis: needs drainage and removal of implants. Duration of antifungals at least 6 weeks.

=== Fluconazole Susceptibility ===
{| class="wikitable"
!Species!!Resistance pattern
|-
|-
|[[Candida albicans]]|| rowspan="4" |Generally [[fluconazole]] susceptible
| ''C. albicans''
| Generally fluconazole-susceptible
|-
|-
| ''C. dubliniensis''
|[[Candida dubliniensis]]
| Generally fluconazole-susceptible
|-
|-
| ''C. parapsilosis''
|[[Candida parapsilosis]]
| Generally fluconazole-susceptible
|-
|-
|[[Candida tropicalis]]
| ''C. glabrata''
| Often '''fluconazole resistant''', or dose-dependent
|-
|-
|[[Candida glabrata]]||Often '''[[fluconazole]] resistant''', or dose-dependent susceptible
| ''C. tropicalis''
| Generally fluconazole-susceptible
|-
|-
|[[Candida krusei]]||Inherent '''[[fluconazole]] resistance'''
| ''C. krusei''
| Inherent '''fluconazole resistance'''
|-
|-
|[[Candida lusitaniae]]||Often '''[[amphotericin]] resistant''' but [[fluconazole]] susceptible
| ''C. lusitaniae''
| Often '''amphotericin resistant''' but fluconazole-susceptible
|}
|}


* See also [https://doi.org/10.1086/504492 Pharmacology of Systemic Antifungal Agents, CID 2006]
*See also [[Antifungal spectrum of activity]] and [https://doi.org/10.1086/504492 Pharmacology of Systemic Antifungal Agents, CID 2006]

=== Fluconazole-Susceptible Isolates ===


* [[Candidemia]]: [[fluconazole]] 12 mg/kg IV load followed by 6 mg/kg PO/IV daily
== Treatment ==
** Can use [[fluconazole]] 800 mg daily for isolates that show dose-dependent susceptibility
*[[Vaginal candidiasis]]: [[fluconazole]] 150 mg PO once, with or without intravaginal [[clotrimazole]]
*[[Oral thrush]]: [[fluconazole]] 100 mg po daily for 7 to 14 days
*[[Esophageal candidiasis]]: [[fluconazole]] 200 mg PO daily for 14 to 21 days
*[[Urinary tract infection]]: [[fluconazole]] 200 mg po daily for 7 to 14 days
* [[Intra-abdominal infections|Intraabdominal infection]]: [[fluconazole]] 400 mg PO daily


== Further Reading ==
* First-line:
** '''Remove lines!'''
** GGT positive: fluconazole for 2 weeks after first negative blood culture
** GGT negative: move to second-line therapies
* Second-line: micafungin, then amphotericin B (last choice)
* Endophthalmitis: extend course to 4 weeks
* Failure of therapy: double-check for endophthalmitis


* ESCMID guideline for the diagnosis and management of ''Candida'' diseases 2012: non‐neutropenic adult patients. ''Clin Microbiol Infect''. 2012;18(Suppl. 7):19-37. doi: [https://doi.org/10.1111/1469-0691.12039 10.1111/1469-0691.12039]
{{DISPLAYTITLE:''Candida'' species}}
* Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. ''Clin Infect Dis''. 2016;62(4):e1-50: doi: [https://doi.org/10.1093/cid/civ933 10.1093/cid/civ933]
{{DISPLAYTITLE:''Candida''}}
[[Category:Yeasts]]
[[Category:Yeasts]]

Latest revision as of 14:18, 15 September 2023

Background

  • Most common medically-important genus of yeast

Microbiology

Identification

  • Any yeast that has growth on culture (blood, fluid, tissue) or seen on Gram stain gets subcultured to SAB-CG at 35º C.
  • Do wet mount to confirm features of Candida.
  • Microscopy for chlamydospores, pseudohyphae, hyphae, arthroconidia, blastoconidia formation, budding, capsules, pigmentation.
    • C. glabrata is smaller, does not produce hyphae or pseudohyphae, produces blastoconidia, and grows as creamy yeast colonies.
    • Non-glabrata spp. usually exhibit single buddings and can have pseudohyphae (rarely true septate hyphae). Cannot identify species based on microscopy alone.
  • MALDI-ToF (Vitek MS) provides a species. If C. haemolunii or C. famata identified on Vitek, need to rule out C. auris.
    • If Vitek not ≥95% match, or identifies one of the two species above, then repeat the MALDI-ToF and set up Dalmau on cornmeal agar.
  • Dalmau technique: growth in adverse conditions (bile oxgall and corn meal) to help identify differences between species of yeast.
    • Light inoculum of single colony in a #-sign pattern with lines 1 inch apart. Cover streaks with coverslip and tamp down gently. Incubate at room temperature 18-72 hours.
    • Examine after 18-24 hours. Look for thick-walled chlamydospores (terminal refractory circles), blastoconidia morphology, and presence of pseudohyphae. Then continue incubating, examining daily.
  • Old-school enzymatic tests and assimilation assays.
  • Temperature tolerance test at 35-37º C, 42º C, and 45º C
  • Germ tube test: if positive, either C. albicans or C. dubliniensis
Species Colony Conidia Pseudohyphae Other Other Tests
C. albicans White to creamy, raised, pasty, smooth and soft, shiny and moist. May produce mycelial growth called “feet” or “roots”. Blastoconidia globose to oval. Well-developed, abundant with blastoconidia in clusters or grape-like arrangement at septa. Chlamydospores: round, large, thick-walled, usually single and mostly terminal forming on the tip of pseudohyphae, but some may be sessile. True hyphae may be present in older cultures. Growth at 42-45º C.
C. dubliniensis Cream-coloured, glistening, waxy, usually smooth. Blastoconidia subspherical, identical to C. albicans. Well-developed with blastoconidia in grape-like arrangement. Chlamydospores: round, large, thick-walled, usually in pairs, triplets, and clusters of 1-3 and mostly terminal. True hyphae may be present, especially in older culture. Usually no growth at 42-45º C.
C. glabrata Small, white to cream-coloured, shiny, pasty, and smooth. Terminal single budding, oval, and small. Typically arranged in dense groups. Absent, or rudimentary if present
C. krusei Cream-coloured to tannish-white. Flat, dry, ground-glass appearance. Spreading edge with a delicate feathery periphery. Elongate, ellipsoidal to cylindrical. Cells are liberated and arranged parallel to the main axis appearing like logs on the stream. Initially sparse, often present on prolonged incubation. Elondated and slender, with blastoconidia forming a cross-matchstick or treelike branching appearance at the septa.
C. parapsilosis White to creamy, shiny, moist, slightly flat, mostly smooth or partly or entirely wrinkled. Ovoid, single or in small clusters. Usually abundant, but may be slow to grow. Crooked or curved, relatively short, branched chains of pseudohyphae with clusters of blastoconidia at or between septa. Christmas-tree-like arrangement. Occasional presence of large hyphal elements called giant cells.
C. tropicalis Cream-coloured to semiwhite, dull, dry, soft, smooth and creamy. May be wrinkled or have a mycelial fringe near the edge. Can have feet (root mycelium) similar to C. albicans. Oval. Single or in small groups or short chains at or between septa of pseudohyphae. Very active growth. Abundant, long and branched. Blastoconidia produced in verticils from the pseudohyphae. True hyphae may be present.
C. famata White to cream coloured. Ellipsoidal. Absent. Weak growth at 40º C. Does not grow at 42º C.
C. auris White to cream-coloured. Pink to beige on chromogenic agar (depending on the agar). Oval or elongated yeast cells, singly or in pairs or groups. Absent. Grows well at 42º C. Variable growth at 45º C. Cycloheximide-susceptible. Usually fluconazole-resistant.
C. guilliermondii White to tan, slightly heaped, shiny, moist, and usually mucoid with smooth edge. Spherical to ellipsoidal. May be slow growing (up to 10 days), radiating from centre of masses of budding cells. Pseudohyphae not produced. May grow at 42 º C.

Epidemiology

Clinical Manifestations

Fungemia

  • See also candidemia
  • Risk factors include colonization, gastrointestinal mucosal disruption, total parenteral nutrition, and immunosuppression

Oropharyngeal Candidiasis

  • Risk factors include immunosuppression including diabetes, inhaled corticosteroids, and denture used

Esophageal Candidiasis

  • Risk factors include immunosuppression

Vulvovaginal Candidiasis

  • Risk factors include colonization from recent antibiotic use, immunosuppression including diabetes, use of oral contraceptives, and pregnancy

Candidal Infection of Skin and Nails

Cutaneous Congenital Candidiasis

  • Occurs in premature infants
  • Presents as a generalized macular erythematous rash
  • May become pustular, papular, or vescicular
  • May desquamate

Chronic Mucocutaneous Candidiasis

Urinary Tract Infection

  • Occurs in patients with diabetes, with indwelling urinary catheters, urinary obstruction, or recent urological procedures
  • True infection most commonly occurs as a result of hematogenous dissemination rather than ascending infection or in patients who are immunocompromised
  • Candida species are a common contaminant of urine cultures, especially in women with vulvovaginal candidiasis
  • They can also asymptomatically colonize the urinary system, causing asymptomatic candiduria

Pulmonary Infections

  • Can occur from hematogenous spread
  • Primary, isolated candidal pneumonia is very rare, and is associated with aspiration pneumonia
  • Empyema can occur in patients with severe underlying diseases
  • Candidal mediastinitis can happen after thoracic surgery, and is associated with high mortality
  • Laryngitis or epiglottitis is rare and life-threatening

Endocarditis

  • Most common fungal cause of infective endocarditis
  • Risk factors include cardiac surgery, prior endocarditis, valvular disease, prosthetic valve, long-term central line, and intravenous drug use
  • Clinically presents like bacterial endocarditis, but has a higher risk of embolic events
  • Most commonly involves aortic and mitral valves

Pericarditis and Myocarditis

  • Risk factors include thoracic surgery or immunosuppression
  • Myocarditis is rare, occuring via hematogenous spread in immunocompromised patients
    • Can have heart block and shock
  • Pericarditis is also rare, often occurs after thoracic surgery, from hematogenous spread, or from contiguous spread

CNS Infections

Ocular Candidiasis

Bone and Joint Infections

  • Rare cause of osteomyelitis and septic arthritis
  • Usually from hematogenous spread; other risk factors include surgery, trauma, intraarticular injection, or diabetic foot infection
  • Symptoms may only become apparent months after initial hematogenous seeding, especially with vertebral osteomyelitis

Intraabdominal Infection

  • Risk factors include abdominal perforation, abdominal surgery, solid organ transplantation, anastomotic leaks, pancreatitis, and peritoneal dialysis

Investigations

  • Urine culture if concern for cystitis
  • Blood culture
    • Never ignore candidemia!
    • Requires an ophthalmology consult to rule out endophthalmitis (1-3% of cases)
    • Echocardiogram if IVDU or prosthetic valve
  • Germ tube test (GTT)
    • If positive, indicates Candida albicans or Candida dubliniensis
    • Identifies fluconazole-sensitive Candidae

Management

  • Invasive infections should be treated with an echinocandin until species and susceptibilities are available

Management by Site of Infection

  • Superficial infections involving skin or mucosa: can be treated with either topical preparations or low-dose oral fluconazole
  • Candidemia: see management of candidemia
  • Bone and joint infections
    • Osteomyelitis: likely needs surgical debridement and removal of any implants. Duration of antifungals not well studied, but likely 3 to 12 months
    • Septic arthritis: needs drainage and removal of implants. Duration of antifungals at least 6 weeks.

Fluconazole Susceptibility

Species Resistance pattern
Candida albicans Generally fluconazole susceptible
Candida dubliniensis
Candida parapsilosis
Candida tropicalis
Candida glabrata Often fluconazole resistant, or dose-dependent susceptible
Candida krusei Inherent fluconazole resistance
Candida lusitaniae Often amphotericin resistant but fluconazole susceptible

Fluconazole-Susceptible Isolates

Further Reading

  • ESCMID guideline for the diagnosis and management of Candida diseases 2012: non‐neutropenic adult patients. Clin Microbiol Infect. 2012;18(Suppl. 7):19-37. doi: 10.1111/1469-0691.12039
  • Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1-50: doi: 10.1093/cid/civ933